Benzinga Value Investor Gave Subscribers a 40% Gain on Transcept Pharmaceuticals

Transcept Pharmaceuticals gained over 40% today when the company announced that it will resubmit its sleep drug, Intermezzo, to the FDA. The FDA permitted Transcept's plan to alter dosage and approved its safety.

If you want to get trading ideas like this, subscribe to Benzinga's Value Investor today!

On July 13th, Transcept Pharmaceuticals TSPT tumbled over 70% after the FDA rejected its insomnia drug, Intermezzo. On August 3rd and 4th, Benzinga Value Investor made an entry into Transcept. The reason being, the company was trading below its cash value and knew Transcept would eventually resubmit its insomnia drug to the FDA.

On September 14, the company announced its plan to resubmit Intermezzo new drug application. Transcept did not plan to conduct additional studies prior to resubmission, which saved it millions of dollars.

Benzinga Value Investor exited the position for a 40% gain! Shares of Transcept continued to rocket 50% more throughout the day, potentially doubling the position! This proves that value investors put themselves in situations to succeed and even make great profits while trading with less-than-ideal entries and exits.

With Benzinga's Value Investor, you receive important, little known information that will change your investment life forever. Get diligent research about the little known, overlooked stocks with long-term growth potential.

Benzinga's value investor adds value you your pockets with well thought-out stock recommendations. Watch as in-depth analysis of a company's financial, social, and industrial position can help you understand the areas where your hard-earned dollars can reap maximum annual returns.

Not everyone can predict the market, but we can give you the edge to make smart decisions based on finance and accounting principles.

If you want to get trading ideas like this, subscribe to Benzinga's Value Investor today!